Synlogic, Inc.
NASDAQ:SYBX
1.32 (USD) • At close February 4, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Synlogic, Inc. |
Symbool | SYBX |
Munteenheid | USD |
Prijs | 1.32 |
Beurswaarde | 15,438,852 |
Dividendpercentage | 0% |
52-weken bereik | 1.22 - 3.698 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc |
Website | https://www.synlogictx.com |
An error occurred while fetching data.
Over Synlogic, Inc.
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)